{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:25:24Z","timestamp":1787977524846,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Horizon Therapeutics plc"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ajo.2019.07.021","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T19:54:11Z","timestamp":1564689251000},"page":"281-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["A New Era in the Treatment of Thyroid Eye Disease"],"prefix":"10.1016","volume":"208","author":[{"given":"Amy","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huasheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2019.07.021_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","article-title":"Psychosocial morbidity of Graves' orbitopathy","volume":"63","author":"Kahaly","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.021_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/ICU.0b013e3283499446","article-title":"The pathophysiology of thyroid eye disease: implications for immunotherapy","volume":"22","author":"Douglas","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"issue":"18","key":"10.1016\/j.ajo.2019.07.021_bib3","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.021_bib4","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/JME-17-0276","article-title":"IGF1 receptor and thyroid-associated ophthalmopathy","volume":"61","author":"Mohyi","year":"2018","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"10.1016\/j.ajo.2019.07.021_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14728222.2017.1288215","article-title":"TSHR as a therapeutic target in Graves' disease","volume":"21","author":"Smith","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ajo.2019.07.021_bib6","doi-asserted-by":"crossref","first-page":"249125","DOI":"10.1155\/2015\/249125","article-title":"Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management","volume":"2015","author":"Barrio-Barrio","year":"2015","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.07.021_bib7","first-page":"543","article-title":"Update on thyroid eye disease and management","volume":"3","author":"Bothun","year":"2009","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2019.07.021_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye (Lond)"},{"issue":"3-4","key":"10.1016\/j.ajo.2019.07.021_bib9","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.021_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.021_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40618-017-0608-z","article-title":"Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?","volume":"40","author":"Bartalena","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ajo.2019.07.021_bib12","first-page":"CD009226","article-title":"Rituximab for thyroid-associated ophthalmopathy","volume":"5","author":"Minakaran","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajo.2019.07.021_bib13","first-page":"CD012984","article-title":"Tocilizumab for thyroid eye disease","volume":"11","author":"Hamed Azzam","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.021_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves' ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.021_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.ajo.2019.07.021_bib16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1089\/thy.2017.0365","article-title":"Death by suicide in Graves' disease and Graves' orbitopathy: a nationwide Danish register study","volume":"27","author":"Ferlov-Schwensen","year":"2017","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ajo.2019.07.021_bib17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.1997.7.885","article-title":"Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument","volume":"7","author":"Gerding","year":"1997","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.021_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12886-018-1018-5","article-title":"Severe unilateral orbitopathy in a patient with Hashimoto's thyroiditis\u2014a case report","volume":"19","author":"Cyranska-Chyrek","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ajo.2019.07.021_bib19","doi-asserted-by":"crossref","first-page":"b560","DOI":"10.1136\/bmj.b560","article-title":"Thyroid eye disease","volume":"338","author":"Perros","year":"2009","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.ajo.2019.07.021_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11910-012-0256-9","article-title":"Thyroid eye disease: towards an evidence base for treatment in the 21st century","volume":"12","author":"Gillespie","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/j.ajo.2019.07.021_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","article-title":"Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy","volume":"26","author":"Smith","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.021_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.07.021_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fendo.2016.00167","article-title":"Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy","volume":"7","author":"Smith","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.ajo.2019.07.021_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.ajo.2019.07.021_bib25","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ajo.2019.07.021_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/21678707.2018.1521268","article-title":"Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?","volume":"6","author":"Smith","year":"2018","journal-title":"Expert Opin Orphan Drugs"},{"issue":"3","key":"10.1016\/j.ajo.2019.07.021_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/eye.2012.284","article-title":"Acute thyroid eye disease (TED): principles of medical and surgical management","volume":"27","author":"Verity","year":"2013","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.021_bib28","doi-asserted-by":"crossref","first-page":"e0176064","DOI":"10.1371\/journal.pone.0176064","article-title":"Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.021_bib29","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00330-014-3103-3","article-title":"Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg","volume":"24","author":"Politi","year":"2014","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.ajo.2019.07.021_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/bjo.2004.050807","article-title":"Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy","volume":"89","author":"Boschi","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.07.021_bib31","series-title":"Orbital Decompression","author":"Baldeschi","year":"2017"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.021_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-2007-967751","article-title":"Thyroid-associated orbitopathy","volume":"21","author":"Alsuhaibani","year":"2007","journal-title":"Semin Plast Surg"},{"issue":"suppl 1","key":"10.1016\/j.ajo.2019.07.021_bib33","article-title":"\u03b2-Arrestin 1 dependent TSH\/IGF1 receptor crosstalk in Graves\u2019 orbital fibroblasts","volume":"28","author":"Krieger","year":"2018","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ajo.2019.07.021_bib34","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ajo.2019.07.021_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajo.2019.07.021_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2019.07.021_bib37","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ajo.2019.07.021_bib38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.021_bib39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy","volume":"14","author":"Marino","year":"2004","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ajo.2019.07.021_bib40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajo.2019.07.021_bib41","first-page":"7146","article-title":"Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy","author":"Russell","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.021_bib42","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T\u00a0cells from patients with Graves' disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.ajo.2019.07.021_bib43","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.ajo.2019.07.021_bib44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/thy.2007.0404","article-title":"Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy","volume":"18","author":"Smith","year":"2008","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ajo.2019.07.021_bib45","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.ajo.2019.07.021_bib46","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.ajo.2019.07.021_bib47","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajo.2019.07.021_bib48","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1210\/jc.2014-3566","article-title":"Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins","volume":"100","author":"Krieger","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajo.2019.07.021_bib49","author":"Treatment of Graves' Orbitopathy"},{"key":"10.1016\/j.ajo.2019.07.021_bib50","author":"Douglas","year":"2019"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419303824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419303824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:41:35Z","timestamp":1757598095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419303824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":50,"alternative-id":["S0002939419303824"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2019.07.021","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A New Era in the Treatment of Thyroid Eye Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2019.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Horizon Therapeutics plc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}